Literature DB >> 25160932

HIV-1 induces B-cell activation and class switch recombination via spleen tyrosine kinase and c-Jun N-terminal kinase pathways.

Ana Judith Perisé-Barrios1, Rafael Correa-Rocha, Susana Alvarez, Maria Angeles Muñoz-Fernandez, Marjorie Pion.   

Abstract

OBJECTIVE: Patients infected by the HIV type 1 (HIV-1) frequently show a general deregulation of immune system. A direct influence of HIV-1 particles on B-cell activation, proliferation and B-cell phenotype alterations has been recently described. Moreover, expression of activation-induced cytidinedeaminase (AID) mRNA, which is responsible for class switch recombination (CSR) and somatic hypermutation (SHM), was reported to be overexpressed in B cells exposed to HIV-1.
DESIGN: Study of primary human B cells in an in-vitro model.
METHODS: In the current study, we evaluated which signalling pathways are activated in primary B cells after a direct contact with HIV-1 particles in vitro using different kinase inhibitors.
RESULTS: Here, we report that B-cell activation together with the increase of AID mRNA expression and the subsequent class switch recombination (CSR) in HIV-exposed B cells occurred through spleen tyrosine kinase (SYK) and c-Jun N-terminal kinase (JNK) pathways.
CONCLUSION: Therefore, we showed that HIV-1 could directly induce primary B-cell deregulation via SYK/B-cell receptor (BCR) engagement, and that activation was followed by the JNK pathway activation. To our knowledge, these data provide the first evidence that SYK/BCR activation was the first step for B-cell activation and CSR mechanism after HIV-1 stimulation in a T-cell-free context. 2014 Wolters Kluwer Health | Lippincott Williams & Wilkins

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25160932     DOI: 10.1097/QAD.0000000000000442

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  1 in total

1.  Human immunodeficiency virus type-1 induces a regulatory B cell-like phenotype in vitro.

Authors:  Jacobo Lopez-Abente; Adrián Prieto-Sanchez; Maria-Ángeles Muñoz-Fernandez; Rafael Correa-Rocha; Marjorie Pion
Journal:  Cell Mol Immunol       Date:  2017-07-17       Impact factor: 11.530

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.